Essity AB
ESSITY A
ISIN SE0009922156 / Valor 36846754
Essity AB
UMushroom community rating:
About company
Essity AB is a leading global hygiene and health company operating through three main segments: Professional Hygiene, Health & Medical, and Consumer Goods. In the Professional Hygiene division, Essity delivers sustainable hygiene management solutions, including dispensing systems for tissues, soaps, and sanitizers, alongside wiping and cleaning products tailored for businesses and public spaces. The Health & Medical segment provides essential products and services such as incontinence care, wound care, compression therapy, and orthopedics, supporting patients, caregivers, and healthcare professionals throughout the continuum of care. Additionally, the Consumer Goods division offers personal and home hygiene products, including baby care, feminine care, incontinence care, and consumer tissue products, addressing the needs of consumers at all life stages. This diversified portfolio enables Essity to maintain a significant presence in both professional and consumer markets, promoting clean and healthy environments worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (19.01.2026):
Essity AB — Quarter 4, 2024: In Q4 2024 Essity AB reported net sales of SEK 37,805m (+3.2% YoY) with organic growth of 3.9% and EBITA of SEK 4,585m (‑1% YoY). Excluding items affecting comparability (IAC), EBITA rose to SEK 4,969m (+2%) with an EBITA margin excl. IAC of 13.1% (down 0.2 pp). For full‑year 2024 net sales were SEK 145,546m (‑1.1%), EBITA rose to SEK 19,475m (+17%) and EBITA excl. IAC to SEK 20,344m (+8%), with a full‑year EBITA margin excl. IAC of 14.0%.
Q4 2024 — sales and margins
Q4 net sales SEK 37,805m (+3.2%); organic growth 3.9% (volume +1.7%, price/mix +2.2%). EBITA excl. IAC SEK 4,969m (+2%), EBITA margin excl. IAC 13.1% (‑0.2 pp). Reported EBITA was SEK 4,585m (IAC mainly restructuring: SEK ‑384m).
Full‑year 2024 — profit improvement
Full‑year net sales SEK 145,546m (‑1.1%); organic growth 0.2% (0.5% volume, ‑0.3% price/mix). EBITA SEK 19,475m (+17%); EBITA excl. IAC SEK 20,344m (+8%) and margin excl. IAC 14.0% (+1.2 pp). ROCE rose to 16.9% (from 14.4%).
Profit, EPS and one‑off divestment
Profit for total operations SEK 21,048m (2023: 9,796) — boosted by ~SEK 9bn capital gain from the divestment of Vinda. Profit for continuing operations SEK 12,033m. Earnings per share (continuing) SEK 17.09 (2023: 13.44); Q4 EPS continuing SEK 4.13 (4.04).
Cash flow and balance sheet
Operating cash flow for 2024 SEK 17,242m (‑3%); net cash flow for continuing operations SEK 25,635m. Net debt fell to SEK 30,769m (from SEK 53,703) largely due to the Vinda divestment (proceeds ~SEK 19,360m). Net debt/EBITDA excl. IAC ~1.16.
Capital allocation — dividend and buybacks
The Board proposes a dividend of SEK 8.25 per share (+6.5%). Share buybacks in 2024: repurchased 7,398,000 Class B shares for SEK 2,224m (Q4 repurchase SEK 1,016m as part of a SEK 3bn program).
Business‑area highlights (Q4)
Health & Medical: organic +5.6%, EBITA excl. IAC SEK 1,361m (+21%), margin 18.3%. Consumer Goods: organic +4.5%, EBITA excl. IAC SEK 2,245m (‑13%), margin pressure from raw material/USD costs. Professional Hygiene: organic +1.4% (5.1% excl. restructuring), EBITA excl. IAC SEK 1,817m (+19%), margin 18.3%.
Costs, IAC and management
Full‑year cost savings ~SEK 1.5bn; currency (notably USD strengthening) and higher raw material costs weighed on margins, especially in Consumer Tissue. IAC mostly restructuring: Q4 IAC ‑SEK 384m, full‑year IAC ‑SEK 939m. CEO Magnus Groth will leave Essity during 2025 (one‑year notice).
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1863 M
Market cap (USD)
6,886
Daily traded volume (Shares)
297 / 293.5
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
